For Institutions
- Corporate Services
- Developers
Download
Help
About

Markets

Information

Academy

Options & Futures

IPO Subscription

Structured Products

Investment Wiki

Affiliate Program

Promotions

EN

English

简体中文

繁體中文

繁體中文（廣東話）Posts & comments will be shown in Cantonese

Search...

Quote List Quote List

Amplify Weight Loss Drug & Treatment ETF(THNR.US)

Last Updated 19:00:00 ET

longbridge loading

Company Encyclopedia

View More

Amplify Weight Loss Drug & Treatment ETF

THNR.US

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

© 2026 Longbridge｜Disclaimer

Schedules & Filings

Schedules

Filings

Dec31

Distribution Plan(EST)

Cash dividend 0.4131 USD

Dec30

Distribution Plan(EST)

Cash dividend 0.4131 USD

Distribution Plan(EST)

Cash dividend 0.4131 USD

View More

Event Tracking

Jan19

Lilly expects an FDA approval decision for its oral obesity drug orforglipron in Q2 2026

16:52

Oral semaglutide sees explosive sales after US market launch

15:12

Hybio Pharmaceutical secures a 180 million RMB order for GLP-1 API, with market speculation pointing to Novo Nordisk as the client

14:52

Guardant Health Inc. Collaborates with Merck to Develop Cancer Therapies

13:05

Novo Nordisk's oral semaglutide approved for new indication in Canada

12:41

Lilly was rumored to be in major acquisition talks at JPM Conference, but no official announcement was made

12:21